GB0201882D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0201882D0
GB0201882D0 GBGB0201882.8A GB0201882A GB0201882D0 GB 0201882 D0 GB0201882 D0 GB 0201882D0 GB 0201882 A GB0201882 A GB 0201882A GB 0201882 D0 GB0201882 D0 GB 0201882D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
formula
pharmaceutically acceptable
acceptable salt
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0201882.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0201882.8A priority Critical patent/GB0201882D0/en
Publication of GB0201882D0 publication Critical patent/GB0201882D0/en
Priority to JP2003563538A priority patent/JP4398731B2/ja
Priority to PT03704474T priority patent/PT1471916E/pt
Priority to HK05103443.2A priority patent/HK1072192B/en
Priority to AT03704474T priority patent/ATE399555T1/de
Priority to DK03704474T priority patent/DK1471916T3/da
Priority to DE60321888T priority patent/DE60321888D1/de
Priority to EP03704474A priority patent/EP1471916B1/en
Priority to US10/502,534 priority patent/US20060264443A1/en
Priority to PCT/EP2003/000802 priority patent/WO2003063844A2/en
Priority to RU2004126447/15A priority patent/RU2322238C2/ru
Priority to CNA038028808A priority patent/CN1646130A/zh
Priority to NZ534137A priority patent/NZ534137A/en
Priority to ES03704474T priority patent/ES2309299T3/es
Priority to CA2473158A priority patent/CA2473158C/en
Priority to MXPA04007309A priority patent/MXPA04007309A/es
Priority to SI200331369T priority patent/SI1471916T1/sl
Priority to KR1020047011580A priority patent/KR101030416B1/ko
Priority to PL370264A priority patent/PL212137B1/pl
Priority to BR0307286-0A priority patent/BR0307286A/pt
Priority to ZA2004/05323A priority patent/ZA200405323B/en
Priority to IL162983A priority patent/IL162983A/en
Priority to NO20043585A priority patent/NO328255B1/no
Priority to US12/328,013 priority patent/US20090131382A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0201882.8A 2002-01-28 2002-01-28 Organic compounds Ceased GB0201882D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds
BR0307286-0A BR0307286A (pt) 2002-01-28 2003-01-27 Tratamento de artrite reumatóide usando imatinib
RU2004126447/15A RU2322238C2 (ru) 2002-01-28 2003-01-27 Лечение ревматоидного артрита
NZ534137A NZ534137A (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using monomethanesulfonate salt of imatinib
HK05103443.2A HK1072192B (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinib
AT03704474T ATE399555T1 (de) 2002-01-28 2003-01-27 Behandlung der rheumatoiden arthritis mit imitanib
DK03704474T DK1471916T3 (da) 2002-01-28 2003-01-27 Behandling af rheumatoid arthritis under anvendelse af imatinib
DE60321888T DE60321888D1 (cg-RX-API-DMAC7.html) 2002-01-28 2003-01-27
EP03704474A EP1471916B1 (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinib
US10/502,534 US20060264443A1 (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis
PCT/EP2003/000802 WO2003063844A2 (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinie
JP2003563538A JP4398731B2 (ja) 2002-01-28 2003-01-27 関節リウマチの処置
CNA038028808A CN1646130A (zh) 2002-01-28 2003-01-27 类风湿性关节炎的治疗
PT03704474T PT1471916E (pt) 2002-01-28 2003-01-27 Tratamento da artrite reumatóide
ES03704474T ES2309299T3 (es) 2002-01-28 2003-01-27 Tratamiento de la artritis reumatoide usando imatinib.
CA2473158A CA2473158C (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinib
MXPA04007309A MXPA04007309A (es) 2002-01-28 2003-01-27 Tratamiento de artritis reumatoide.
SI200331369T SI1471916T1 (sl) 2002-01-28 2003-01-27 Zdravljenje revmatoidnega artritisa z imatinibom
KR1020047011580A KR101030416B1 (ko) 2002-01-28 2003-01-27 류마티스성 관절염의 치료
PL370264A PL212137B1 (pl) 2002-01-28 2003-01-27 Zastosowanie monometanosulfonianu 4-(4-metylopiperazyn-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu
ZA2004/05323A ZA200405323B (en) 2002-01-28 2004-07-05 Treatment of rheumatoid arthritis using imatinib
IL162983A IL162983A (en) 2002-01-28 2004-07-12 Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
NO20043585A NO328255B1 (no) 2002-01-28 2004-08-27 Anvendelsen av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid og kombinasjoner av denne forbindelsen for fremstilling av preparater for behandling av reumatoid artritt.
US12/328,013 US20090131382A1 (en) 2002-01-28 2008-12-04 Treatment of rheumatoid arthritis using imatinib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds

Publications (1)

Publication Number Publication Date
GB0201882D0 true GB0201882D0 (en) 2002-03-13

Family

ID=9929858

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0201882.8A Ceased GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds

Country Status (22)

Country Link
US (2) US20060264443A1 (cg-RX-API-DMAC7.html)
EP (1) EP1471916B1 (cg-RX-API-DMAC7.html)
JP (1) JP4398731B2 (cg-RX-API-DMAC7.html)
KR (1) KR101030416B1 (cg-RX-API-DMAC7.html)
CN (1) CN1646130A (cg-RX-API-DMAC7.html)
AT (1) ATE399555T1 (cg-RX-API-DMAC7.html)
BR (1) BR0307286A (cg-RX-API-DMAC7.html)
CA (1) CA2473158C (cg-RX-API-DMAC7.html)
DE (1) DE60321888D1 (cg-RX-API-DMAC7.html)
DK (1) DK1471916T3 (cg-RX-API-DMAC7.html)
ES (1) ES2309299T3 (cg-RX-API-DMAC7.html)
GB (1) GB0201882D0 (cg-RX-API-DMAC7.html)
IL (1) IL162983A (cg-RX-API-DMAC7.html)
MX (1) MXPA04007309A (cg-RX-API-DMAC7.html)
NO (1) NO328255B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ534137A (cg-RX-API-DMAC7.html)
PL (1) PL212137B1 (cg-RX-API-DMAC7.html)
PT (1) PT1471916E (cg-RX-API-DMAC7.html)
RU (1) RU2322238C2 (cg-RX-API-DMAC7.html)
SI (1) SI1471916T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003063844A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200405323B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003226209B2 (en) * 2002-03-21 2008-10-23 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
US20050130986A1 (en) * 2003-11-21 2005-06-16 Eklund Kari K. Treatment of spondylarthropathies
PL1805510T3 (pl) * 2004-09-08 2012-07-31 Immunaid Pty Ltd Strategia terapeutyczna leczenia chorób autoimmunologicznych i zwyrodnieniowych
US20080032989A1 (en) * 2006-05-31 2008-02-07 Robinson William H Method of treating inflammatory diseases using tyroskine kinase inhibitors
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
RU2580656C1 (ru) * 2014-11-20 2016-04-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1414500A4 (en) * 2001-04-16 2005-01-12 Uab Research Foundation Akt and regulation of ra synovial fibroblast apoptosis
US20040167134A1 (en) * 2001-05-16 2004-08-26 Christian Bruns Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
DE60212627T2 (de) * 2001-06-29 2007-06-14 Ab Science Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung von entzündlichen Krankheiten

Also Published As

Publication number Publication date
US20090131382A1 (en) 2009-05-21
BR0307286A (pt) 2004-12-28
CN1646130A (zh) 2005-07-27
JP4398731B2 (ja) 2010-01-13
EP1471916B1 (en) 2008-07-02
DE60321888D1 (cg-RX-API-DMAC7.html) 2008-08-14
IL162983A (en) 2010-06-16
CA2473158C (en) 2013-06-11
RU2322238C2 (ru) 2008-04-20
NO20043585L (no) 2004-10-21
EP1471916A2 (en) 2004-11-03
ZA200405323B (en) 2005-08-31
KR20040086301A (ko) 2004-10-08
PT1471916E (pt) 2008-10-03
DK1471916T3 (da) 2008-10-20
ATE399555T1 (de) 2008-07-15
SI1471916T1 (sl) 2008-12-31
PL370264A1 (en) 2005-05-16
NZ534137A (en) 2007-03-30
RU2004126447A (ru) 2005-07-10
KR101030416B1 (ko) 2011-04-20
MXPA04007309A (es) 2005-09-12
US20060264443A1 (en) 2006-11-23
CA2473158A1 (en) 2003-08-07
WO2003063844A2 (en) 2003-08-07
PL212137B1 (pl) 2012-08-31
JP2005526022A (ja) 2005-09-02
NO328255B1 (no) 2010-01-18
WO2003063844A3 (en) 2004-04-01
ES2309299T3 (es) 2008-12-16
HK1072192A1 (en) 2005-08-19

Similar Documents

Publication Publication Date Title
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
MY129772A (en) Crystal modification of a n-phenyl- 2 - pyrimidineamine derivative, processes for its manufacture and its use
IL164678A (en) High-drug tablet containing 4– (4-methylpiprazine – 1-ylamethyl) -n - [(4-methyl-3– (4-pyridin-3-il) pyrimidine-2-ylamino) phenyl] -benzamide or compatible salt Its pharmaceutical and process for its preparation
EA200600928A1 (ru) Фармацевтически приемлемые соли хинолиноновых соединений с улучшенными фармацевтическими свойствами
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
GB0201882D0 (en) Organic compounds
BR0316126A (pt) Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
NZ543709A (en) Use of tyrosine kinase inhibitor to treat diabetes
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
HK1097535A (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
AR039782A1 (es) Derivado de la tamsulosina

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)